View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Alpine Select AG: 1 director

A director at Alpine Select AG sold/bought 26,480 shares at 8.700CHF and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

Jan Frederik Slijkerman ... (+5)
  • Jan Frederik Slijkerman
  • Jeroen van den Broek
  • Jesse Norcross
  • Nadège Tillier
  • Timothy Rahill

Coffee, Croissants & Credit/EnBW, Enel, Verizon, Merlin Properties, Co...

Utilities: EnBW 9M25 financial performance slightly down. Enel 9M25 financials in line with expectations. Telecom: Verizon reportedly preparing job cuts. Real Estate: Merlin Properties 9M25: Good results with a strong Madrid office market. Colonial 9M25: Solid results, prime CBD office exposure continues to perform well

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Genelux Corporation Reports Third Quarter 2025 Financial Results and P...

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates -- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 -- -- Cash, cash equivalents, short-term investments and restricted cash of $21.0 million as of September 30, 2025 -- WESTLAKE VILLAGE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third...

 PRESS RELEASE

Macerich Reports Third Quarter 2025 Earnings Results

Macerich Reports Third Quarter 2025 Earnings Results SANTA MONICA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- The Macerich Company (NYSE: MAC) has released its Third Quarter 2025 Earnings Results and Supplemental Information by posting it to the Investor Relations section of its website at . As previously announced, management will hold a conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) today, Tuesday, November 4, 2025, to discuss quarterly results. Participants who wish to join the conference by telephone must register using the dial-in registration link below to receiv...

 PRESS RELEASE

Macerich Declares the Quarterly Dividend on Its Common Shares

Macerich Declares the Quarterly Dividend on Its Common Shares SANTA MONICA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of the Macerich Company (NYSE: MAC) declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on December 29, 2025, to stockholders of record at the close of business on December 15, 2025. About Macerich Macerich is a fully integrated, self-managed, self-administered real estate investment trust (REIT). As a leading owner, operator, and developer of high-quality retail real estate in densely populated and attrac...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 29, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Macerich Schedules Third Quarter 2025 Earnings Release and Conference ...

Macerich Schedules Third Quarter 2025 Earnings Release and Conference Call SANTA MONICA, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- WHAT: Macerich (NYSE: MAC) Schedules Third Quarter 2025 Earnings Release and Conference Call WHEN: Earnings Results will be released after market on Tuesday, November 4, 2025. Management will hold a conference call at 2:00 pm Pacific Time (5:00 pm Eastern Time) on that same day to discuss quarterly results. WHERE: Participants who wish to join the conference by telephone must register using the dial-in registration link below to receive the dial-in number ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 27, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Macerich To Present at BofA Securities 2025 Global Real Estate Confere...

Macerich To Present at BofA Securities 2025 Global Real Estate Conference SANTA MONICA, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- The Macerich Company (NYSE: MAC) today announced that the Company will present at the BofA Securities 2025 Global Real Estate Conference in New York, NY, on Tuesday, September 9, 2025 at 1:30 p.m. Eastern The live audio-only webcast will be available online in the of the Company’s website at . An online replay will be available following the presentation at the same location. About MacerichMacerich is a fully integrated, self-managed, self-administ...

 PRESS RELEASE

Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwrig...

Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference WESTLAKE VILLAGE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that , President, CEO and Chairman of the Board and , Chief Financial Officer, will participate in a fireside chat at H.C. Wainwright & Co’s Annual Global Investment Conference on Tuesday, September 9, 2025. Biotech Equity Research Analyst, Emily Bodnar, will moderate the session which is scheduled to begin at 2:30 p.m. ET. To register for and view ...

Macerich Co: 1 director

A director at Macerich Co sold 9,500 shares at 17.165USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

 PRESS RELEASE

Macerich Reports Second Quarter 2025 Results

Macerich Reports Second Quarter 2025 Results SANTA MONICA, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- The Macerich Company (NYSE: MAC) has released its Second Quarter 2025 Earnings Results and Supplemental Information by posting it to the Investor Relations section of its website at . As previously announced, management will hold a conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) today, Monday, August 11, 2025, to discuss quarterly results. Participants who wish to join the conference by telephone must register using the dial-in registration link below to receive the dia...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Genelux Corporation Reports Second Quarter 2025 Financial Results and ...

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates. Momentum continued to build across the Company, as it looks forward to a series of key clinical readouts over the next year. These readouts are intended to further demonstrate the ability of Olvi-Vec to resensitize tumors to frontline platinum-based regimens. G...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch